Physician profile
Basel Taha
NPI 1720391113
$7,153.50
in general payments reported to CMS, 2019-2025
31 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $418 · 2021: $930 · 2022: $1,171 · 2023: $1,006 · 2024: $1,335 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,139.65 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,047.41 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $601.69 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $512.70 | 2019-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $498.51 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $460.30 | 2019-2025 | Jynarque |
| Amgen INC. | $453.60 | 2019-2025 | Tavneos, Krystexxa |
| Horizon Therapeutics Plc | $373.58 | 2021-2023 | Krystexxa |
| Novo Nordisk INC | $339.83 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Vifor Pharma, INC. | $316.92 | 2019-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.17 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $285.34 | 2020-2025 | Benlysta, Arexvy |
| Travere Therapeutics, INC. | $280.12 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $250.19 | 2023-2025 | |
| Ardelyx, INC. | $225.82 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Calliditas Therapeutics US INC. | $215.50 | 2022-2025 | Tarpeyo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $187.11 | 2020-2022 | |
| Recor Medical INC | $148.43 | 2024 | Paradise Renal Denervation System |
| Opko Pharmaceuticals, LLC | $134.25 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $101.34 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $93.05 | 2019-2025 | Velphoro |
| Genentech USA, INC. | $54.00 | 2025 | Gazyva |
| Akebia Therapeutics INC | $49.08 | 2019-2024 | Vafseo |
| Daiichi Sankyo INC. | $48.62 | 2023-2024 | Injectafer |
| Alnylam Pharmaceuticals INC. | $45.58 | 2023-2025 | Oxlumo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.22 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $25.25 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $22.35 | 2025 | |
| Mallinckrodt Enterprises LLC | $21.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2023 | Gattex |
| Ultragenyx Pharmaceutical INC. | $14.72 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basel Taha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.